文献速递胸部肿瘤

他雷替尼在ROS1阳性非小细胞肺癌中的长期疗效与安全性:II期TRUST-I研究结果

Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study.
PubMed 文献 · J Clin Oncol · 2026-04-21

TRUST-I研究评估他雷替尼治疗晚期ROS1阳性非小细胞肺癌中国患者的长期疗效与安全性。在103例TKI初治患者中,客观缓解率为90.3%,中位缓解持续时间和无进展生存期均超过4年,中位总生存期未达到。在66例克唑替尼经治患者中,客观缓解率为51.5%,中位总生存期为25.6个月。安全性特征与既往报告一致,未发现新的安全性信号。

要点

  • TKI初治患者客观缓解率达90.3%,中位缓解持续时间和无进展生存期均超过4年。
  • 克唑替尼经治患者客观缓解率为51.5%,中位总生存期为25.6个月。
  • 安全性特征与既往报告一致,未发现新的安全性信号。

核心结论

  • 他雷替尼在晚期ROS1阳性非小细胞肺癌患者中显示出持久的长期疗效和可控的安全性。

研究设计与样本

  • II期TRUST-I研究纳入中国晚期ROS1阳性非小细胞肺癌患者,评估他雷替尼600 mg每日一次口服的长期疗效与安全性。

主要发现

  • 103例TKI初治患者中位随访51.0个月,客观缓解率为90.3%(95% CI 82.9至95.3),中位缓解持续时间和中位无进展生存期分别为49.7个月和49.6个月,中位总生存期未达到。
  • 66例克唑替尼经治患者中位随访45.2个月,客观缓解率为51.5%,中位缓解持续时间为13.2个月,中位无进展生存期为7.6个月,中位总生存期为25.6个月。
  • 安全性特征与既往报告一致,未发现新的安全性信号。

临床怎么用

  • 他雷替尼可作为TKI初治或克唑替尼经治的晚期ROS1阳性非小细胞肺癌患者的治疗选择,需关注长期随访中的疗效维持和安全性管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Taletrectinib is a next-generation, CNS-active, selective ROS1 tyrosine kinase inhibitor (TKI) with activity against the ROS1 G2032R resistance mutation. Initial data from the TRUST-I study (ClinicalTrials.gov identifier: NCT04395677) demonstrated high response rates and intracranial (IC) activity, with promising durability, in Chinese patients with advanced ROS1+ non-small cell lung cancer (NSCLC). With longer follow-up, taletrectinib continued to demonstrate high and durable response rates in both TKI-naïve and crizotinib-pretreated patients, including IC activity and promising overall survival (OS). Among 103 TKI-naïve patients who started taletrectinib at 600 mg once daily (median follow-up, 51.0 months), the objective response rate (ORR) was 90.3% (95% CI, 82.9 to 95.3), the median duration of response (DOR) and median progression-free survival (PFS) exceeded 4 years (49.7 months and 49.6 months, respectively), and median OS was not reached. Among 66 crizotinib-pretreated patients (median follow-up, 45.2 months), the ORR was 51.5%, the median DOR was 13.2 months, the median PFS was 7.6 months, and the median OS was 25.6 months. The safety profile remained consistent with prior reports, and no new safety signals were identified. Overall, taletrectinib demonstrated durable long-term efficacy and a manageable safety profile in patients with advanced ROS1+ NSCLC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Li W, Zhang Y, Fan H, et al. Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study. J Clin Oncol. 2026. PMID: 42013573. doi:10.1200/JCO-26-00434

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。